

Xiao-Jun Huang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3422887/publications.pdf>

Version: 2024-02-01

579
papers

16,531
citations

23567

58
h-index

42399

92
g-index

615
all docs

615
docs citations

615
times ranked

9429
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of socio-demographic co-variates on prognosis, tyrosine kinase-inhibitor use and outcomes in persons with newly-diagnosed chronic myeloid leukaemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 449-459.	2.5	3
2	Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation. <i>Leukemia</i> , 2022, 36, 267-270.	7.2	14
3	Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?. <i>Leukemia</i> , 2022, 36, 482-491.	7.2	17
4	Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation. <i>Acta Haematologica</i> , 2022, 145, 54-62.	1.4	6
5	Development and validation of a mortality predicting scoring system for severe aplastic anaemia patients receiving haploidentical allogeneic transplantation. <i>British Journal of Haematology</i> , 2022, 196, 735-742.	2.5	3
6	Donor activating killer cell immunoglobulin-like receptors genes correlated with Epstein-Barr virus reactivation after haploidentical haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2022, 196, 1007-1017.	2.5	4
7	Preemptive Interferon- γ Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies. <i>Frontiers in Immunology</i> , 2022, 13, 757002.	4.8	13
8	Significance of WT1 and multiparameter flow cytometry assessment in patients with chronic myelomonocytic leukemia receiving allogeneic hematopoietic stem cell transplantation. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 510-517.	1.3	3
9	Treatment outcome and efficacy of therapeutic plasma exchange for transplant-associated thrombotic microangiopathy in a large real-world cohort study. <i>Bone Marrow Transplantation</i> , 2022, , .	2.4	5
10	Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome. <i>BMC Cancer</i> , 2022, 22, 11.	2.6	2
11	Efficacy and safety of mesenchymal stem cells treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072110728.	2.5	8
12	Donor NKG2C homozygosity contributes to CMV clearance after haploidentical transplantation. <i>JCI Insight</i> , 2022, 7, .	5.0	8
13	Comparable anti-CMV responses of transplant donor and third-party CMV-specific T cells for treatment of CMV infection after allogeneic stem cell transplantation. <i>Cellular and Molecular Immunology</i> , 2022, 19, 482-491.	10.5	15
14	Long-term follow-up of haploidentical transplantation in relapsed/refractory severe aplastic anemia: a multicenter prospective study. <i>Science Bulletin</i> , 2022, 67, 963-970.	9.0	15
15	Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysis. <i>American Journal of Hematology</i> , 2022, 97, 458-469.	4.1	19
16	Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 572-578.	2.4	4
17	Integrated genomic analyses identify high-risk factors and actionable targets in T-cell acute lymphoblastic leukemia. <i>Blood Science</i> , 2022, 4, 16-28.	0.9	8
18	Recombinant human thrombopoietin increases platelet count in severe thrombocytopenic patients with hepatitis B-related cirrhosis: Multicentre real-world observational study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 306-316.	2.0	4

#	ARTICLE	IF	CITATIONS
19	Haploidentical hematopoietic stem cell transplantation may improve long-term survival for children with high-risk T-cell acute lymphoblastic leukemia in first complete remission. Chinese Medical Journal, 2022, 135, 940-949.	2.3	4
20	A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy. Leukemia, 2022, 36, 1336-1342.	7.2	11
21	Recipient and donor PTX3 rs2305619 polymorphisms increase the susceptibility to invasive fungal disease following haploidentical stem cell transplantation: a prospective study. BMC Infectious Diseases, 2022, 22, 292.	2.9	2
22	Adoptive therapy with <scp>cytomegalovirus</scp>-specific T cells for <scp>cytomegalovirus</scp> infection after haploidentical stem cell transplantation and factors affecting efficacy. American Journal of Hematology, 2022, 97, 762-769.	4.1	14
23	A Predicted Model for Refractory/Recurrent Cytomegalovirus Infection in Acute Leukemia Patients After Haploidentical Hematopoietic Stem Cell Transplantation. Frontiers in Cellular and Infection Microbiology, 2022, 12, 862526.	3.9	7
24	Role of allogeneic haematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukaemia in the era of immunotherapy. Chinese Medical Journal, 2022, 135, 890-900.	2.3	7
25	Functional Competence of NK Cells via the KIR/MHC Class I Interaction Correlates with DNAM-1 Expression. Journal of Immunology, 2022, 208, 492-500.	0.8	5
26	Dysfunctional bone marrow endothelial progenitor cells are involved in patients with myelodysplastic syndromes. Journal of Translational Medicine, 2022, 20, 144.	4.4	3
27	The Interaction of HLA-C1/KIR2DL2/L3 Promoted KIR2DL2/L3 Single-Positive/NKC2C-Positive Natural Killer Cell Reconstitution, Raising the Incidence of aGVHD after Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2022, 13, 814334.	4.8	3
28	Prophylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label randomized trial. BMC Medicine, 2022, 20, 140.	5.5	8
29	The Incidence, Outcomes, and Risk Factors of Secondary Poor Graft Function in Haploidentical Hematopoietic Stem Cell Transplantation for Acquired Aplastic Anemia. Frontiers in Immunology, 2022, 13, .	4.8	4
30	A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation. Experimental Hematology and Oncology, 2022, 11, 25.	5.0	19
31	Independent prognostic significance of <scp>TP53</scp> mutations in adult acute myeloid leukaemia with complex karyotype. International Journal of Laboratory Hematology, 2022, , .	1.3	4
32	Combination of <i>KIT</i> and <i>FLT3</i>ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission. Hematological Oncology, 2022, 40, 724-733.	1.7	2
33	Bulsufan decreases the incidence of mixed chimaerism in HLA-matched donor transplantation for severe aplastic anaemia. Bone Marrow Transplantation, 2022, 57, 1204-1206.	2.4	5
34	Co-variables associated with outcomes of tyrosine kinase-inhibitor therapy in persons with chronic myeloid leukaemia initially presenting in accelerated phase. Leukemia, 2022, 36, 1818-1824.	7.2	6
35	Naturally Selected CD7 CAR-T Therapy without Genetic Manipulations for T-ALL/LBL: First-in-human Phase I Clinical Trial. Blood, 2022, , .	1.4	36
36	CMV infection combined with acute GVHD associated with poor CD8+ T-cell immune reconstitution and poor prognosis post-HLA-matched allo-HSCT. Clinical and Experimental Immunology, 2022, 208, 332-339.	2.6	6

#	ARTICLE	IF	CITATIONS
37	Multiomics Analysis Identifies SOCS1 as Restraining T Cell Activation and Preventing Graft-versus-Host Disease. <i>Advanced Science</i> , 2022, 9, e2200978.	11.2	7
38	An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study. <i>Blood</i> , 2022, 140, 516-520.	1.4	18
39	Predictive scoring systems for molecular responses in persons with chronic phase chronic myeloid leukemia receiving initial imatinib therapy. <i>Leukemia</i> , 2022, 36, 2042-2049.	7.2	4
40	Comparable clinical outcomes of haploidentical hematopoietic stem cell transplantation in patients with hepatitis-associated aplastic anemia and non-hepatitis-associated aplastic anemia. <i>Annals of Hematology</i> , 2022, 101, 1815-1823.	1.8	3
41	Decoding lymphomyeloid divergence and immune hyporesponsiveness in G-CSF-primed human bone marrow by single-cell RNA-seq. <i>Cell Discovery</i> , 2022, 8, .	6.7	5
42	Anti-PD-1 antibody (sintilimab) plus decitabine as first-line treatment for patients with higher-risk myelodysplastic syndrome (MDS): Preliminary results from a single-arm, open-label, phase II study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7052-7052.	1.6	0
43	The loss or absence of minimal residual disease of $\leq 1\%$ at any time after two cycles of consolidation chemotherapy in <i>CBFB-MYH11</i> -positive acute myeloid leukaemia indicates poor prognosis. <i>British Journal of Haematology</i> , 2021, 192, 265-271.	2.5	13
44	Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide. <i>Annals of Hematology</i> , 2021, 100, 169-180.	1.8	14
45	Ethnic and geographic diversity of chronic lymphocytic leukaemia. <i>Leukemia</i> , 2021, 35, 433-439.	7.2	21
46	The incidence, clinical outcome, and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia. <i>Clinical Transplantation</i> , 2021, 35, e14160.	1.6	12
47	Haploidentical stem cell transplantation for aplastic anemia: the current advances and future challenges. <i>Bone Marrow Transplantation</i> , 2021, 56, 779-785.	2.4	23
48	Gut microbiome alterations and its link to corticosteroid resistance in immune thrombocytopenia. <i>Science China Life Sciences</i> , 2021, 64, 766-783.	4.9	10
49	Haploidentical hematopoietic stem cell transplantation for patients with myeloid sarcoma: a single center retrospective study. <i>Annals of Hematology</i> , 2021, 100, 799-808.	1.8	2
50	Human herpesvirus 6 reactivation in unmanipulated haploidentical hematopoietic stem cell transplantation predicts the occurrence of grade II to IV acute graft-versus-host disease. <i>Transplant Infectious Disease</i> , 2021, 23, e13544.	1.7	5
51	Cellular immunotherapy for hematological malignancy: recent progress and future perspectives. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	3.0	6
52	Prognosis and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. <i>Annals of Hematology</i> , 2021, 100, 505-516.	1.8	4
53	Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center. <i>Annals of Hematology</i> , 2021, 100, 1203-1212.	1.8	10
54	Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	31

#	ARTICLE	IF	CITATIONS
55	Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation Compared With Chemotherapy as Postremission Treatment of Children With Intermediate-risk Acute Myeloid Leukemia in First Complete Remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e126-e136.	0.4	5
56	Pre-transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors. <i>Cancer Communications</i> , 2021, 41, 333-344.	9.2	5
57	Haploidentical Stem Cell Transplantation With a Novel Conditioning Regimen in Older Patients: A Prospective Single-Arm Phase 2 Study. <i>Frontiers in Oncology</i> , 2021, 11, 639502.	2.8	4
58	Disease Risk Comorbidity Index for Patients Receiving Haploidentical Allogeneic Hematopoietic Transplantation. <i>Engineering</i> , 2021, 7, 162-169.	6.7	11
59	HCMV modulates c-Mpl/IL-3 pathway-mediated megakaryo/thrombopoiesis via PDGFR α and β receptors after allo-HSCT. <i>Journal of Cellular Physiology</i> , 2021, 236, 6726-6741.	4.1	1
60	Wilms tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. <i>BMC Cancer</i> , 2021, 21, 292.	2.6	5
61	Overcoming graft failure after haploidentical transplantation: Is this a possibility?. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101255.	1.7	5
62	A risk score system for stratifying the risk of relapse in B cell acute lymphocytic leukemia patients after allogeneic stem cell transplantation. <i>Chinese Medical Journal</i> , 2021, 134, 1199-1208.	2.3	3
63	G-CSF-Primed Peripheral Blood Stem Cell Haploidentical Transplantation Could Achieve Satisfactory Clinical Outcomes for Acute Leukemia Patients in the First Complete Remission: A Registered Study. <i>Frontiers in Oncology</i> , 2021, 11, 631625.	2.8	8
64	Acute Cholecystitis Following Allogeneic Hematopoietic Stem Cell Transplantation: Clinical Features, Outcomes, Risk Factors, and Prediction Model. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 253.e1-253.e9.	1.2	1
65	The Prognostic Significance of ZNF384 Fusions in Adult Ph-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: A Comprehensive Cohort Study From a Single Chinese Center. <i>Frontiers in Oncology</i> , 2021, 11, 632532.	2.8	9
66	Minimal residual disease monitoring and preemptive immunotherapies for frequent 11q23 rearranged acute leukemia after allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2021, 100, 1267-1281.	1.8	3
67	Risk factors and outcomes of diffuse alveolar haemorrhage after allogeneic haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2097-2107.	2.4	9
68	Clinical risk score for predicting invasive fungal disease after allogeneic hematopoietic stem cell transplantation: Analysis of the China Assessment of Antifungal Therapy in Hematological Diseases (CAESAR) study. <i>Transplant Infectious Disease</i> , 2021, 23, e13611.	1.7	7
69	Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy. <i>Leukemia</i> , 2021, 35, 3092-3100.	7.2	22
70	The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy. <i>British Journal of Haematology</i> , 2021, 193, 1060-1075.	2.5	13
71	The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 67.	6.2	9
72	Optimizing outcomes for haploidentical hematopoietic stem cell transplantation in severe aplastic anemia with intensive GVHD prophylaxis: a review of current findings. <i>Expert Review of Hematology</i> , 2021, 14, 449-455.	2.2	5

#	ARTICLE	IF	CITATIONS
73	Predictive Value of Dynamic Peri-Transplantation MRD Assessed By MFC Either Alone or in Combination with Other Variables for Outcomes of Patients with T-Cell Acute Lymphoblastic Leukemia. <i>Current Medical Science</i> , 2021, 41, 443-453.	1.8	3
74	Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial. <i>Science Bulletin</i> , 2021, 66, 2498-2505.	9.0	44
75	Graft Failure in Patients With Hematological Malignancies: A Successful Salvage With a Second Transplantation From a Different Haploidentical Donor. <i>Frontiers in Medicine</i> , 2021, 8, 604085.	2.6	13
76	M2 macrophages, but not M1 macrophages, support megakaryopoiesis by upregulating PI3K-AKT pathway activity. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 234.	17.1	37
77	β ₁ T Cells May Aggravate Acute Graft-Versus-Host Disease Through CXCR4 Signaling After Allogeneic Hematopoietic Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 687961.	4.8	5
78	Real-world assessment of the effectiveness of posaconazole for the prophylaxis and treatment of invasive fungal infections in hematological patients. <i>Medicine (United States)</i> , 2021, 100, e26772.	1.0	4
79	Second unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed acute leukemia post-chemotherapy plus modified donor lymphocyte infusion. <i>Frontiers of Medicine</i> , 2021, 15, 728-739.	3.4	0
80	Comparison of the clinical outcomes between NIMA-mismatched and NIPA-mismatched haploidentical hematopoietic stem cell transplantation for patients with hematological malignancies. <i>Bone Marrow Transplantation</i> , 2021, 56, 2723-2731.	2.4	4
81	Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment. <i>Annals of Hematology</i> , 2021, 100, 2557-2566.	1.8	4
82	Interferon-β as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2949-2956.	1.3	14
83	Improved function and balance in T cell modulation by endothelial cells in young people. <i>Clinical and Experimental Immunology</i> , 2021, 206, 196-207.	2.6	4
84	Risk Stratification of Cytogenetically Normal Acute Myeloid Leukemia With Biallelic CEBPA Mutations Based on a Multi-Gene Panel and Nomogram Model. <i>Frontiers in Oncology</i> , 2021, 11, 706935.	2.8	3
85	PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study. <i>British Journal of Haematology</i> , 2021, 195, 722-730.	2.5	3
86	Hepatitis B Seropositive Status in Recipients or Donors Is Not Related to Worse Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 668.e1-668.e9.	1.2	3
87	Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group. <i>Bone Marrow Transplantation</i> , 2021, 56, 2940-2947.	2.4	43
88	Clinical risk factors and prognostic model for idiopathic inflammatory demyelinating diseases after haploidentical hematopoietic stem cell transplantation in patients with hematological malignancies. <i>American Journal of Hematology</i> , 2021, 96, 1407-1419.	4.1	5
89	Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-Versus-Host Disease. <i>Frontiers in Immunology</i> , 2021, 12, 749266.	4.8	12
90	The Potential Roles of Mucosa-Associated Invariant T Cells in the Pathogenesis of Gut Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 720354.	4.8	14

#	ARTICLE	IF	CITATIONS
91	The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. <i>Journal of Hematology and Oncology</i> , 2021, 14, 145.	17.0	124
92	A prognostic model (BATAP) with external validation for patients with transplant-associated thrombotic microangiopathy. <i>Blood Advances</i> , 2021, 5, 5479-5489.	5.2	6
93	All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e688-e699.	4.6	19
94	A Scoring System for Predicting the Prognosis of Late-Onset Severe Pneumonia after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 870.e1-870.e7.	1.2	2
95	Overt gastrointestinal bleeding following haploidentical haematopoietic stem cell transplantation: incidence, outcomes and predictive models. <i>Bone Marrow Transplantation</i> , 2021, 56, 1341-1351.	2.4	8
96	Allogeneic hematopoietic stem cell transplantation for intermediate-risk acute myeloid leukemia in the first remission: outcomes using haploidentical donors are similar to those using matched siblings. <i>Annals of Hematology</i> , 2021, 100, 555-562.	1.8	5
97	Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1172-1185.	10.5	55
98	A modified conditioning regimen based on low-dose cyclophosphamide and fludarabine for haploidentical hematopoietic stem cell transplant in severe aplastic anemia patients at risk of severe cardiotoxicity. <i>Clinical Transplantation</i> , 2021, , e14514.	1.6	3
99	Haploidentical Stem Cell Transplantation for Acute Myeloid Leukemia: Current Therapies, Challenges and Future Prospective. <i>Frontiers in Oncology</i> , 2021, 11, 758512.	2.8	11
100	Optimizing Allogeneic Grafts in Hematopoietic Stem Cell Transplantation. <i>Stem Cells Translational Medicine</i> , 2021, 10, S41-S47.	3.3	9
101	Prognostic value of RASD1 transcript levels in adult Philadelphia-negative B-cell acute lymphoblastic leukemia. <i>Hematology</i> , 2021, 26, 9-15.	1.5	0
102	All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP. <i>Blood</i> , 2021, , .	1.4	10
103	A Clinical Study of 15 Acute Leukemia Patients with Plasmacytoid Dendritic Cells Expansion. <i>Blood</i> , 2021, 138, 4468-4468.	1.4	0
104	The Application of Decitabine in Combination with G-CSF, Low-Dose Cytarabine and Aclarubicin in AML-MRC: A Single Center Case Control Study. <i>Blood</i> , 2021, 138, 2320-2320.	1.4	0
105	The Potential Roles of Mucosa-Associated Invariant T Cells in the Pathogenesis of Gut Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 1686-1686.	1.4	0
106	Haploidentical transplantation has a superior graft-versus-leukemia effect than HLA-matched sibling transplantation for Philadelphia-negative high-risk B-cell acute lymphoblastic leukemia. <i>Chinese Medical Journal</i> , 2021, Publish Ahead of Print, .	2.3	4
107	Endothelial Cell Dysfunction Is Involved in the Progression of Myelodysplastic Syndromes. <i>Blood</i> , 2021, 138, 3668-3668.	1.4	1
108	Chimeric Antigen Receptor T Cell Therapy Improve the Prognosis of Pediatric Acute Lymphoblastic Leukemia With Persistent/Recurrent Minimal Residual Disease in First Complete Remission. <i>Frontiers in Immunology</i> , 2021, 12, 731435.	4.8	4

#	ARTICLE	IF	CITATIONS
109	Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Oncology</i> , 2021, 11, 773394.	2.8	8
110	First-line Therapy With Donor-derived Human Cytomegalovirus (HCMV)-specific T Cells Reduces Persistent HCMV Infection by Promoting Antiviral Immunity After Allogeneic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2020, 70, 1429-1437.	5.8	30
111	NK cell reconstitution following unmanipulated HLA-mismatched/haploidentical transplantation compared with matched sibling transplantation. <i>Science China Life Sciences</i> , 2020, 63, 781-784.	4.9	5
112	The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 12-24.	2.4	94
113	Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF/ATG and posttransplant cyclophosphamide: results from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG). <i>Science China Life Sciences</i> , 2020, 63, 571-581.	4.9	26
114	The Quantification of Minimal Residual Disease Pre- and Post-Unmanipulated Haploidentical Allograft by Multiparameter Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 75-87.	1.5	18
115	Influence of the degree of donor bone marrow hyperplasia on patient clinical outcomes after allogeneic hematopoietic stem cell transplantation. <i>Science China Life Sciences</i> , 2020, 63, 138-147.	4.9	4
116	Haploidentical hematopoietic cell transplantation for severe acquired aplastic anemia: a case-control study of post-transplant cyclophosphamide included regimen vs. anti-thymocyte globulin & colony-stimulating factor-based regimen. <i>Science China Life Sciences</i> , 2020, 63, 940-942.	4.9	15
117	Improved survival after offspring donor transplant compared with older aged-matched siblings for older leukaemia patients. <i>British Journal of Haematology</i> , 2020, 189, 153-161.	2.5	8
118	Basiliximab as Treatment for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients after Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 351-357.	2.0	20
119	Effects of Granulocyte Colony-Stimulating Factor on Proliferation and Apoptosis of B Cells in Bone Marrow of Healthy Donors. <i>Transplantation Proceedings</i> , 2020, 52, 345-352.	0.6	2
120	Incidence, Risk Factors, Outcomes, and Risk Score Model of Acute Pancreatitis after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1171-1178.	2.0	8
121	Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as post-remission treatment for children with very high-risk philadelphia chromosome negative B-cell acute lymphoblastic leukaemia in first complete remission. <i>British Journal of Haematology</i> , 2020, 188, 757-767.	2.5	17
122	Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. <i>Leukemia</i> , 2020, 34, 1433-1443.	7.2	73
123	Subgroup Analysis Can Optimize the Relapse-Prediction Cutoff Value for WT1 Expression After Allogeneic Hematologic Stem Cell Transplantation in Acute Myeloid Leukemia. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 188-195.	2.8	4
124	The predictive value of minimal residual disease when facing the inconsistent results detected by real-time quantitative PCR and flow cytometry in NPM1-mutated acute myeloid leukemia. <i>Annals of Hematology</i> , 2020, 99, 73-82.	1.8	15
125	Unmanipulated haploidentical hematopoietic stem cell transplantation for children with myelodysplastic syndrome. <i>Pediatric Transplantation</i> , 2020, 24, e13864.	1.0	5
126	Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. <i>Cytotherapy</i> , 2020, 22, 755-761.	0.7	33

#	ARTICLE	IF	CITATIONS
127	COVID-19 & allogeneic transplant: Activity and preventive measures for best outcomes in China. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e94.	0.9	3
128	Therapeutic Approaches for Acute Promyelocytic Leukaemia: Moving Towards an Orally Chemotherapy-Free Era. <i>Frontiers in Oncology</i> , 2020, 10, 586004.	2.8	7
129	Preemptive interferon- γ treatment could protect against relapse and improve long-term survival of ALL patients after allo-HSCT. <i>Scientific Reports</i> , 2020, 10, 20148.	3.3	7
130	Valproic acid enhances pamidronate-sensitized cytotoxicity of $\text{V}\alpha 2+$ T cells against EBV-related lymphoproliferative cells. <i>International Immunopharmacology</i> , 2020, 88, 106890.	3.8	2
131	The incidence, risk factors, and outcomes of acute graft-versus-host disease in pediatric T-cell-replete haploidentical hematopoietic stem cell transplantation. <i>Pediatric Transplantation</i> , 2020, 24, e13793.	1.0	1
132	Comparison of different cytomegalovirus diseases following haploidentical hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 2659-2670.	1.8	13
133	Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1655-1662.	2.0	8
134	Th2 polarization in target organs is involved in the alleviation of pathological damage mediated by transplanting granulocyte colony-stimulating factor-primed donor T cells. <i>Science China Life Sciences</i> , 2020, 64, 1087-1096.	4.9	4
135	Comparison of haplo-SCT and chemotherapy for young adults with standard-risk Ph-negative acute lymphoblastic leukemia in CR1. <i>Journal of Hematology and Oncology</i> , 2020, 13, 52.	17.0	13
136	Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody. <i>Bone Marrow Transplantation</i> , 2020, 55, 1326-1336.	2.4	31
137	Comparison of hemorrhagic and ischemic stroke after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 2087-2097.	2.4	8
138	Arsenic trioxide alleviates acute graft-versus-host disease by modulating macrophage polarization. <i>Science China Life Sciences</i> , 2020, 63, 1744-1754.	4.9	14
139	Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes. <i>Bone Marrow Transplantation</i> , 2020, 55, 2035-2042.	2.4	11
140	Development and validation of a prediction model (AHC) for early identification of refractory thrombotic thrombocytopenic purpura using nationally representative data. <i>British Journal of Haematology</i> , 2020, 191, 269-281.	2.5	5
141	miRNA-98-5p Targeting IGF2BP1 Induces Mesenchymal Stem Cell Apoptosis by Modulating PI3K/Akt and p53 in Immune Thrombocytopenia. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 20, 764-776.	5.1	28
142	Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment. <i>BMC Cancer</i> , 2020, 20, 553.	2.6	21
143	Haploidentical-versus identical-sibling transplant for high-risk pediatric AML: A multicenter study. <i>Cancer Communications</i> , 2020, 40, 93-104.	9.2	20
144	Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data. <i>Journal of Hematology and Oncology</i> , 2020, 13, 18.	17.0	36

#	ARTICLE	IF	CITATIONS
145	CD8+CD161hi T cells are associated with acute graft-versus-host disease after haploidentical hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1652-1654.	2.4	3
146	Monocyte subsets in bone marrow grafts may contribute to a low incidence of acute graft-versus-host disease for young donors. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 9204-9216.	3.6	2
147	Serum Lactate Dehydrogenase Can Be Used as a Factor for Re-Evaluating First-Relapsed Multiple Myeloma. <i>Acta Haematologica</i> , 2020, 143, 559-566.	1.4	10
148	Outcomes of symptomatic venous thromboembolism after haploidentical donor hematopoietic stem cell transplantation and comparison with human leukocyte antigen-identical sibling transplantation. <i>Thrombosis Research</i> , 2020, 194, 168-175.	1.7	2
149	Monosomal karyotype is associated with poor outcomes in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia receiving chemotherapy but not allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 1833-1843.	1.8	3
150	Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients With Hematologic Malignancies: A Multicenter, Open-Label, Randomized Controlled Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 3367-3376.	1.6	69
151	Impact of ABO incompatibility on outcomes after haploidentical hematopoietic stem cell transplantation for severe aplastic anemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 1068-1075.	2.4	9
152	Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA. <i>British Journal of Haematology</i> , 2020, 190, 533-544.	2.5	14
153	Prevalence and risk factors of having antibodies to class I and II human leukocyte antigens in older haploidentical allograft candidates. <i>Scientific Reports</i> , 2020, 10, 2367.	3.3	3
154	Mutation topography and risk stratification for <i>de novo</i> acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD). <i>British Journal of Haematology</i> , 2020, 190, 274-283.	2.5	18
155	DPEP1 expression promotes proliferation and survival of leukaemia cells and correlates with relapse in adults with common B cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 190, 67-78.	2.5	11
156	Prognosis of haploidentical hematopoietic stem cell transplantation in non-infant children with t(v;11q23)/MLL-rearranged B-cell acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2020, 91, 106333.	0.8	11
157	Haploidentical stem cell transplantation in patients with chronic myelomonocytic leukemia. <i>Science China Life Sciences</i> , 2020, 63, 1261-1264.	4.9	8
158	Impact of prophylactic/preemptive donor lymphocyte infusion and intensified conditioning for relapsed/refractory leukemia: a real-world study. <i>Science China Life Sciences</i> , 2020, 63, 1552-1564.	4.9	12
159	Frequency, Risk Factors, and Outcome of Active Tuberculosis following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1203-1209.	2.0	9
160	Autophagy in endothelial cells regulates their haematopoiesis-supporting ability. <i>EBioMedicine</i> , 2020, 53, 102677.	6.1	13
161	Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia With a Consideration of Socioeconomic Characteristics: A Retrospective Study From a Single Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e304-e315.	0.4	6
162	Comparable survival outcome between transplantation from haploidentical donor and matched related donor or unrelated donor for severe aplastic anemia patients aged 40 years and older: A retrospective multicenter cohort study. <i>Clinical Transplantation</i> , 2020, 34, e13810.	1.6	16

#	ARTICLE	IF	CITATIONS
163	Incidence, risk factors, and outcomes of cytomegalovirus retinitis after haploidentical hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1147-1160.	2.4	18
164	Fluorescence in situ hybridisation combined with CD138 immunomagnetic sorting is effective to identify cytogenetic abnormalities which play significant prognostic roles in Chinese AL amyloidosis patients. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 208-209.	3.0	3
165	Expanded clinical-grade membrane-bound IL-2/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo. <i>European Journal of Immunology</i> , 2020, 50, 1374-1385.	2.9	22
166	Incidence, Risk Factors, and Outcomes of Primary Prolonged Isolated Thrombocytopenia after Haploidentical Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1452-1458.	2.0	10
167	A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 2649-2657.	1.8	2
168	Treatment and unmet needs in steroid-refractory acute graft-versus-host disease. <i>Leukemia</i> , 2020, 34, 1229-1240.	7.2	73
169	Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting V γ 2+T cells activities after hematopoietic transplantation for blood malignancies. , 2020, 8, e000208.		18
170	Osteoclast stimulatory transmembrane protein (OC-STAMP) is a promising molecular prognostic indicator for multiple myeloma. <i>European Journal of Haematology</i> , 2020, 105, 185-195.	2.2	2
171	Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute <scp>graft-versus-host disease</scp>: Updated experience from a large-scale study. <i>American Journal of Hematology</i> , 2020, 95, 927-936.	4.1	32
172	Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study. <i>Journal of Hematology and Oncology</i> , 2020, 13, 27.	17.0	48
173	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2020, 105, 47-58.	3.5	51
174	Different Effects of Pre-transplantation Measurable Residual Disease on Outcomes According to Transplant Modality in Patients With Philadelphia Chromosome Positive ALL. <i>Frontiers in Oncology</i> , 2020, 10, 320.	2.8	17
175	Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus Was Associated With Poor Prognosis After Allogeneic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 620891.	4.8	21
176	Comparison of central nervous system relapse outcomes following haploidentical vs identical-sibling transplant for acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2020, 99, 1643-1653.	1.8	3
177	Prognostic significance of SET-NUP214 fusion gene in acute leukemia after allogeneic hematopoietic stem cell transplantation. <i>Medicine (United States)</i> , 2020, 99, e23569.	1.0	6
178	Mutations Based on Next-Generation Sequencing May be Complementally to Prognostic Risk in Myelodysplastic Syndromes. <i>Blood</i> , 2020, 136, 42-43.	1.4	0
179	The Prognostic Significance of Wilms' Tumor Gene 1 in Adult AML with Different Risk Stratification Following Allo-HSCT. <i>Blood</i> , 2020, 136, 4-5.	1.4	0
180	Fluconazole is as effective as other anti-mold agents in preventing early invasive fungal disease after allogeneic stem cell transplantation: assessment of antifungal therapy in haematological disease in China. <i>Translational Cancer Research</i> , 2020, 9, 6900-6911.	1.0	0

#	ARTICLE	IF	CITATIONS
181	Both the Subtypes of Kit Mutation and Minimal Residual Disease Are Associated with Prognosis in Core Banding Factor Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 4-5.	1.4	0
182	Comparison of efficacy between HLA6/6- and HLA3/6-matched haploidentical hematopoietic stem cell transplant in T-cell-replete transplants between parents and children. <i>Science China Life Sciences</i> , 2019, 62, 104-111.	4.9	6
183	The significance of peri-transplantation minimal residual disease assessed by multiparameter flow cytometry on outcomes for adult AML patients receiving haploidentical allografts. <i>Bone Marrow Transplantation</i> , 2019, 54, 567-577.	2.4	19
184	Monoclonal gammopathy of undetermined significance in Chinese population: A prospective epidemiological study. <i>Hematological Oncology</i> , 2019, 37, 75-79.	1.7	7
185	Quantity and Quality Reconstitution of NKG2A+ Natural Killer Cells Are Associated with Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1-11.	2.0	24
186	Modification of donor lymphocyte infusion: how to improve the outcome?. <i>Science China Life Sciences</i> , 2019, 62, 1253-1256.	4.9	6
187	Seeking biomarkers for acute graft-versus-host disease: where we are and where we are heading?. <i>Biomarker Research</i> , 2019, 7, 17.	6.8	13
188	Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study. <i>BMC Medicine</i> , 2019, 17, 156.	5.5	55
189	High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia. <i>Cancer Medicine</i> , 2019, 8, 5459-5467.	2.8	7
190	Myeloid-derived suppressor cells in hematological malignancies: friends or foes. <i>Journal of Hematology and Oncology</i> , 2019, 12, 105.	17.0	70
191	Update of the "Beijing Protocol" haplo-identical hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 703-707.	2.4	28
192	Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients. <i>Journal of Hematology and Oncology</i> , 2019, 12, 88.	17.0	76
193	Who is the best haploidentical donor for acquired severe aplastic anemia? Experience from a multicenter study. <i>Journal of Hematology and Oncology</i> , 2019, 12, 87.	17.0	24
194	The prognostic significance of Wilms' tumor gene 1 (WT1) expression at diagnosis in adults with Ph-negative B cell precursor acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2019, 98, 2551-2559.	1.8	8
195	Risk factors for chronic graft-versus-host disease after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation in acute myeloid leukemia. <i>Frontiers of Medicine</i> , 2019, 13, 667-679.	3.4	2
196	Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1310-1318.	2.4	38
197	Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts. <i>American Journal of Hematology</i> , 2019, 94, 512-521.	4.1	51
198	All-trans retinoic acid protects mesenchymal stem cells from immune thrombocytopenia by regulating the complement-interleukin-1 β loop. <i>Haematologica</i> , 2019, 104, 1661-1675.	3.5	25

#	ARTICLE	IF	CITATIONS
199	Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia. <i>Bone Marrow Transplantation</i> , 2019, 54, 1319-1326.	2.4	35
200	G-CSF-induced macrophage polarization and mobilization may prevent acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1419-1433.	2.4	40
201	Minimal residual disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. <i>Frontiers of Medicine</i> , 2019, 13, 354-364.	3.4	8
202	FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients. <i>Bone Marrow Transplantation</i> , 2019, 54, 1462-1470.	2.4	9
203	Donor selection for haploidentical hematopoietic cell transplantation—practice guidance. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e42.	0.9	0
204	MAGE genes: Prognostic indicators in AL amyloidosis patients. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 5672-5678.	3.6	6
205	Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation. <i>Annals of Hematology</i> , 2019, 98, 1877-1883.	1.8	20
206	A new era of allogeneic hematopoietic stem cell transplantation. <i>Seminars in Hematology</i> , 2019, 56, 171-172.	3.4	0
207	Delay expression of NKp30 on NK cells correlates with long-term mycophenolate mofetil treatment and higher EBV viremia post allogeneic hematological stem cells transplantation. <i>Clinical Immunology</i> , 2019, 205, 49-56.	3.2	6
208	Incidence, risk factors and outcomes of sinusoidal obstruction syndrome after haploidentical allogeneic stem cell transplantation. <i>Annals of Hematology</i> , 2019, 98, 1733-1742.	1.8	6
209	Incidence, Risk Factors, and Outcome of Immune-Mediated Neuropathies (IMNs) following Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1629-1636.	2.0	6
210	Early myeloid-derived suppressor cells (HLA-DR ^{low} /CD33 ⁺ CD16 ⁺) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT. <i>Journal of Hematology and Oncology</i> , 2019, 12, 31.	17.0	35
211	Incidence and predictors of severe cardiotoxicity in patients with severe aplastic anaemia after haploidentical haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1694-1700.	2.4	9
212	S100A16 suppresses the growth and survival of leukaemia cells and correlates with relapse and relapse free survival in adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2019, 185, 836-851.	2.5	7
213	Donor-Derived CD19-Targeted T Cell Infusion Eliminates B Cell Acute Lymphoblastic Leukemia Minimal Residual Disease with No Response to Donor Lymphocytes after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Engineering</i> , 2019, 5, 150-155.	6.7	8
214	Reduced Î2-GPI is associated with increased platelet aggregation and activation in patients with prolonged isolated thrombocytopenia after allo-HSCT. <i>Science China Life Sciences</i> , 2019, 62, 921-929.	4.9	2
215	Positive stool culture could predict the clinical outcomes of haploidentical hematopoietic stem cell transplantation. <i>Frontiers of Medicine</i> , 2019, 13, 492-503.	3.4	5
216	Comparable Outcomes after Hematopoietic Stem Cell Transplantation from Mother Donors and Matched Unrelated Donors in Patients with Hematopoietic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1210-1217.	2.0	2

#	ARTICLE	IF	CITATIONS
217	Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations. <i>Leukemia and Lymphoma</i> , 2019, 60, 2181-2189.	1.3	15
218	Dysregulated megakaryocyte distribution associated with nestin+ mesenchymal stem cells in immune thrombocytopenia. <i>Blood Advances</i> , 2019, 3, 1416-1428.	5.2	18
219	Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation. <i>Blood Advances</i> , 2019, 3, 1303-1317.	5.2	43
220	Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation. <i>Blood Advances</i> , 2019, 3, 4312-4325.	5.2	27
221	Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia. <i>Blood Advances</i> , 2019, 3, 3406-3418.	5.2	8
222	Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase. <i>Scientific Reports</i> , 2019, 9, 17601.	3.3	13
223	Granulocyte Colony-Stimulating Factor-Primed Unmanipulated Haploidentical Blood and Marrow Transplantation. <i>Frontiers in Immunology</i> , 2019, 10, 2516.	4.8	36
224	Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy. <i>Oncologist</i> , 2019, 24, e1141-e1147.	3.7	14
225	Comparison of outcomes after human leukocyte antigen-matched and haploidentical hematopoietic stem-cell transplantation for multiple myeloma. <i>Chinese Medical Journal</i> , 2019, 132, 1765-1772.	2.3	4
226	Comparison analysis between haplo identical stem cell transplantation and matched sibling donor stem cell transplantation for high-risk acute myeloid leukemia in first complete remission. <i>Science China Life Sciences</i> , 2019, 62, 691-697.	4.9	16
227	Is human leukocyte antigen-matched sibling donor transplant always better than haploidentical allograft?. <i>Seminars in Hematology</i> , 2019, 56, 201-208.	3.4	10
228	New approaches in allogeneic transplantation in AML. <i>Seminars in Hematology</i> , 2019, 56, 147-154.	3.4	9
229	A novel recombinant human thrombopoietin for treating prolonged isolated thrombocytopenia after allogeneic stem cell transplantation. <i>Platelets</i> , 2019, 30, 994-1000.	2.3	10
230	B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src/STAT3 and c-Cbl-mediated degradation of SOCS3. <i>Leukemia</i> , 2019, 33, 1475-1486.	7.2	47
231	Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission. <i>Clinical Cancer Research</i> , 2019, 25, 1737-1748.	7.0	26
232	Hepatitis E virus infection after haploidentical haematopoietic stem cell transplantation: incidence and clinical course. <i>British Journal of Haematology</i> , 2019, 184, 788-796.	2.5	8
233	Effects of Low-Dose Glucocorticoid Prophylaxis on Chronic Graft-versus-Host Disease and Graft-versus-Host Disease-Free, Relapse-Free Survival after Haploidentical Transplantation: Long-Term Follow-Up of a Controlled, Randomized Open-Label Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 529-537.	2.0	11
234	Class I and II human leukocyte antibodies in pediatric haploidentical allograft candidates: prevalence and risk factors. <i>Bone Marrow Transplantation</i> , 2019, 54, 1287-1294.	2.4	7

#	ARTICLE	IF	CITATIONS
235	ADAM28 promotes tumor growth and dissemination of acute myeloid leukemia through IGFBP-3 degradation and IGF-I-induced cell proliferation. <i>Cancer Letters</i> , 2019, 442, 193-201.	7.2	12
236	Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1611-1620.	2.0	30
237	Chemotherapy plus DLI for relapse after haploidentical HSCT: the biological characteristics of relapse influences clinical outcomes of acute leukemia patients. <i>Bone Marrow Transplantation</i> , 2019, 54, 1198-1207.	2.4	12
238	Occurrence and Severity of Donor Lymphocyte Infusion-Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 912-920.	2.0	4
239	Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation. <i>Frontiers of Medicine</i> , 2019, 13, 45-56.	3.4	26
240	Comments on the article: "Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation" (Response to Pan et al.). <i>British Journal of Haematology</i> , 2019, 184, 882-883.	2.5	0
241	Interferon- γ salvage treatment is effective for patients with acute leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation. <i>Frontiers of Medicine</i> , 2019, 13, 238-249.	3.4	18
242	The impact of donor characteristics on the invariant natural killer T cells of granulocyte-colony-stimulating factor-mobilized marrow grafts and peripheral blood grafts. <i>Transplant Immunology</i> , 2018, 48, 55-59.	1.2	3
243	Update on current research into haploidentical hematopoietic stem cell transplantation. <i>Expert Review of Hematology</i> , 2018, 11, 273-284.	2.2	20
244	T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2018, 93, 736-744.	4.1	21
245	Effect of the in vivo application of granulocyte colony-stimulating factor on NK cells in bone marrow and peripheral blood. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 3025-3034.	3.6	15
246	Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study. <i>Cancer Medicine</i> , 2018, 7, 1043-1055.	2.8	32
247	Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1350-1359.	2.0	39
248	N-acetylcysteine improves mesenchymal stem cell function in prolonged isolated thrombocytopenia post-allotransplant. <i>British Journal of Haematology</i> , 2018, 180, 863-878.	2.5	22
249	N-acetylcysteine improves bone marrow endothelial progenitor cells in prolonged isolated thrombocytopenia patients post allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2018, 93, 931-942.	4.1	29
250	Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation. <i>Annals of Hematology</i> , 2018, 97, 967-975.	1.8	27
251	Inverse correlation of T-cell recovery with EBV reactivation after haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2018, 180, 276-285.	2.5	23
252	Atorvastatin enhances bone marrow endothelial cell function in corticosteroid-resistant immune thrombocytopenia patients. <i>Blood</i> , 2018, 131, 1219-1233.	1.4	40

#	ARTICLE	IF	CITATIONS
253	First-line choice for severe aplastic anemia in children: Transplantation from a haploidentical donor vs immunosuppressive therapy. <i>Clinical Transplantation</i> , 2018, 32, e13179.	1.6	29
254	Perianal Infections in the Phase before Engraftment after Allogeneic Hematopoietic Stem Cell Transplantations: A Study of the Incidence, Risk Factors, and Clinical Outcomes. <i>Acta Haematologica</i> , 2018, 139, 19-27.	1.4	9
255	Acute kidney injury following haplo stem cell transplantation: incidence, risk factors and outcome. <i>Bone Marrow Transplantation</i> , 2018, 53, 483-486.	2.4	11
256	Mesenchymal stem cell deficiency influences megakaryocytopoiesis through the TNFAIP3/NF- κ B/SMAD pathway in patients with immune thrombocytopenia. <i>British Journal of Haematology</i> , 2018, 180, 395-411.	2.5	32
257	The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 521-534.	2.4	168
258	Safety and efficacy of haploidentical stem cell transplantation for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2018, 53, 507-510.	2.4	4
259	Impact of HLA allele mismatch at HLA-A, -B, -C, -DRB1, and -DQB1 on outcomes in haploidentical stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 600-608.	2.4	9
260	Plerixafor and granulocyte colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study. <i>Transfusion</i> , 2018, 58, 81-87.	1.6	21
261	Haploidentical Transplantation Using Unmanipulated G-CSF-Primed Blood and Marrow as Allografts: Clinical Data and Challenges. , 2018, , 55-79.		0
262	The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology. <i>Journal of Hematology and Oncology</i> , 2018, 11, 33.	17.0	233
263	The prognostic role of E2A-PBX1 expression detected by real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) in B cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2018, 97, 1547-1554.	1.8	15
264	IgG synthesis rate and anti-myelin oligodendrocyte glycoprotein antibody in CSF may be associated with the onset of CNS demyelination after haplo-HSCT. <i>Annals of Hematology</i> , 2018, 97, 1399-1406.	1.8	6
265	Comparative Analysis of Flow Cytometry and RQ-PCR for the Detection of Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1936-1943.	2.0	25
266	Rapid reconstitution of NK1 cells after allogeneic transplantation is associated with a reduced incidence of graft-versus-host disease. <i>Science China Life Sciences</i> , 2018, 61, 902-911.	4.9	14
267	T cell exhaustion characterized by compromised MHC class I and II restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation. <i>Clinical Immunology</i> , 2018, 190, 32-40.	3.2	24
268	Combined prednisone and levothyroxine improve treatment of severe thrombocytopenia in hepatitis B with compensatory cirrhosis accompanied by subclinical and overt hypothyroidism. <i>Science China Life Sciences</i> , 2018, 61, 924-933.	4.9	1
269	Treatment of late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: the role of corticosteroids. <i>Annals of Hematology</i> , 2018, 97, 1209-1217.	1.8	10
270	Monitoring of post-transplant <i>CBFβ</i> and <i>MYH11</i> as minimal residual disease, rather than <i>KIT</i> mutations, can predict relapse after allogeneic haematopoietic cell transplantation in adults with inv(16) acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2018, 180, 448-451.	2.5	26

#	ARTICLE	IF	CITATIONS
271	The initial level of MLL-partial tandem duplication affects the clinical outcomes in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 967-972.	1.3	12
272	Homeostatic $\hat{I}^3\hat{I}$ T Cell Contents Are Preserved by Granulocyte Colony-Stimulating Factor Priming and Correlate with the Early Recovery of $\hat{I}^3\hat{I}$ T Cell Subsets after Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 252-259.	2.0	12
273	Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 163-168.	2.0	6
274	Platelet transfusion refractoriness after T-cell-replete haploidentical transplantation is associated with inferior clinical outcomes. <i>Science China Life Sciences</i> , 2018, 61, 569-577.	4.9	8
275	Comparison of reference values for immune recovery between event-free patients receiving haploidentical allografts and those receiving human leukocyte antigen-matched sibling donor allografts. <i>Frontiers of Medicine</i> , 2018, 12, 153-163.	3.4	6
276	The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia. <i>Leukemia Research</i> , 2018, 65, 14-19.	0.8	21
277	Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 741-750.	2.0	36
278	Thrombotic microangiopathy with concomitant $\langle scp \rangle GI \langle /scp \rangle$ aGVHD after allogeneic hematopoietic stem cell transplantation: Risk factors and outcome. <i>European Journal of Haematology</i> , 2018, 100, 171-181.	2.2	13
279	Utility of flexible bronchoscopy with polymerase chain reaction in the diagnosis and management of pulmonary infiltrates in allogeneic $\langle scp \rangle HSCT \langle /scp \rangle$ patients. <i>Clinical Transplantation</i> , 2018, 32, e13146.	1.6	8
280	Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation. <i>American Journal of Hematology</i> , 2018, 93, 246-253.	4.1	52
281	Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Chinese Medical Journal</i> , 2018, 131, 2808-2816.	2.3	7
282	Relationship of Cell Compositions in Allografts with Outcomes after Haploidentical Transplantation for Acquired Severe Aplastic Anemia. <i>Chinese Medical Journal</i> , 2018, 131, 2185-2192.	2.3	5
283	Dendritic Cells Are Critical for the Activation and Expansion of \hat{V}^2+ T Cells After Allogeneic Hematopoietic Transplantation. <i>Frontiers in Immunology</i> , 2018, 9, 2528.	4.8	10
284	Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease. <i>Frontiers in Immunology</i> , 2018, 9, 3041.	4.8	50
285	Incidence, Risk Factors, Microbiology and Outcomes of Pre-engraftment Bloodstream Infection After Haploidentical Hematopoietic Stem Cell Transplantation and Comparison With HLA-identical Sibling Transplantation. <i>Clinical Infectious Diseases</i> , 2018, 67, S162-S173.	5.8	36
286	Interferon- \hat{I}^{\pm} Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study. <i>Oncologist</i> , 2018, 23, 1349-1357.	3.7	17
287	The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China. <i>Cancer Letters</i> , 2018, 438, 63-75.	7.2	116
288	Synergistic antitumoral efficacy of a novel replicative adenovirus SG611-PDCD5 and daunorubicin in human leukemic cells. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5121-5132.	2.0	6

#	ARTICLE	IF	CITATIONS
289	Is there an epidemic of chronic lymphocytic leukaemia (CLL) in China?. <i>Leukemia Research</i> , 2018, 73, 16-20.	0.8	13
290	The role of collateral related donors in haploidentical hematopoietic stem cell transplantation. <i>Science Bulletin</i> , 2018, 63, 1376-1382.	9.0	27
291	The clinical features and prognosis of the monoclonal gammopathy undetermined significance: A single center study. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 73, 9-13.	1.4	0
292	Evaluation of HistoCheck as a Predictor of Clinical Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1866-1872.	2.0	1
293	An unbalanced monocyte macrophage polarization in the bone marrow microenvironment of patients with poor graft function after allogeneic haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2018, 182, 679-692.	2.5	36
294	Dysfunctional Bone Marrow Mesenchymal Stem Cells in Patients with Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1981-1989.	2.0	26
295	Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study. <i>BMC Cancer</i> , 2018, 18, 782.	2.6	13
296	Prevalence and outcomes of uncommon <i>BCR-ABL1</i> fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre. <i>British Journal of Haematology</i> , 2018, 182, 693-700.	2.5	31
297	Impairment of bone marrow endothelial progenitor cells in acute graft-versus-host disease patients after allotransplant. <i>British Journal of Haematology</i> , 2018, 182, 870-886.	2.5	15
298	Busulfan, Fludarabine, and Cyclophosphamide (BFC) conditioning allowed stable engraftment after haplo-identical allogeneic stem cell transplantation in children with adrenoleukodystrophy and mucopolysaccharidosis. <i>Bone Marrow Transplantation</i> , 2018, 53, 770-773.	2.4	18
299	Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>British Journal of Haematology</i> , 2018, 183, 411-420.	2.5	27
300	Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with <i>t(8;21)</i> . <i>Blood Cancer Journal</i> , 2018, 8, 76.	6.2	21
301	Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 871-879.	10.7	110
302	Prevalence and risk factors of antibodies to human leukocyte antigens in haploidentical stem cell transplantation candidates: A multi-center study. <i>Human Immunology</i> , 2018, 79, 672-677.	2.4	11
303	Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance. <i>Blood Cancer Journal</i> , 2018, 8, 61.	6.2	10
304	Predicted indirectly recognizable HLA epitopes are not associated with clinical outcomes after haploidentical hematopoietic stem cell transplantation. <i>Human Immunology</i> , 2018, 79, 117-121.	2.4	7
305	High EVI1 Expression Predicts Poor Outcomes in Adult Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk Receiving Chemotherapy. <i>Medical Science Monitor</i> , 2018, 24, 758-767.	1.1	17
306	Efficacy of Caspofungin in Unclassified Invasive Fungal Infection Cases: A Retrospective Analysis of Patients with Hematological Malignancies in China. <i>Medical Science Monitor</i> , 2018, 24, 5258-5270.	1.1	2

#	ARTICLE	IF	CITATIONS
307	Meis1 is critical to the maintenance of human acute myeloid leukemia cells independent of MLL rearrangements. <i>Annals of Hematology</i> , 2017, 96, 567-574.	1.8	19
308	Association between C-reactive protein levels in the first 1–3 days post-transplant and allogeneic immune reactions. <i>Biomarkers in Medicine</i> , 2017, 11, 117-124.	1.4	1
309	The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 44.	17.0	51
310	Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant. <i>Journal of Hematology and Oncology</i> , 2017, 10, 25.	17.0	151
311	Regulatory B cells promote graft-versus-host disease prevention and maintain graft-versus-leukemia activity following allogeneic bone marrow transplantation. <i>Oncolmmunology</i> , 2017, 6, e1284721.	4.6	28
312	Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2017, 102, 1066-1074.	3.5	40
313	Viral encephalitis after haploidentical hematopoietic stem cell transplantation: Causative viral spectrum, characteristics, and risk factors. <i>European Journal of Haematology</i> , 2017, 98, 450-458.	2.2	22
314	Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease—Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1311-1319.	2.0	66
315	IFN- γ Is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Registry Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1303-1310.	2.0	40
316	Recipient–donor KIR ligand matching prevents CMV reactivation post–haploidentical T cell–replete transplantation. <i>British Journal of Haematology</i> , 2017, 177, 766-781.	2.5	21
317	A Retrospective Study of Central Nervous System Invasive Fungal Disease after Allogeneic Stem Cell Transplantation: Risk Factors, Clinical Characteristics, and Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1158-1164.	2.0	8
318	Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (<sc>MRD</sc>) monitoring and <sc>MRD</sc>-directed intervention. <i>British Journal of Haematology</i> , 2017, 179, 184-197.	2.5	40
319	Aberrant T cell responses in the bone marrow microenvironment of patients with poor graft function after allogeneic hematopoietic stem cell transplantation. <i>Journal of Translational Medicine</i> , 2017, 15, 57.	4.4	32
320	Primary fungal prophylaxis in acute leukemia patients with different risk factors: retrospective analysis from the CAESAR study. <i>International Journal of Hematology</i> , 2017, 106, 221-228.	1.6	6
321	Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2017, 96, 829-838.	1.8	39
322	Abnormalities of the Bone Marrow Immune Microenvironment in Patients with Prolonged Isolated Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 906-912.	2.0	25
323	Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial. <i>Cancer</i> , 2017, 123, 2881-2892.	4.1	63
324	Donor-derived <sc>CD</sc>19-targeted T cell infusion induces minimal residual disease–negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2017, 179, 598-605.	2.5	87

#	ARTICLE	IF	CITATIONS
325	Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes. <i>Oncolimmunology</i> , 2017, 6, e1356152.	4.6	28
326	Impaired Function of Bone Marrow Mesenchymal Stem Cells from Immune Thrombocytopenia Patients in Inducing Regulatory Dendritic Cell Differentiation Through the Notch-1/Jagged-1 Signaling Pathway. <i>Stem Cells and Development</i> , 2017, 26, 1648-1661.	2.1	36
327	Cytomegalovirus-Specific T-Cell Transfer for Refractory Cytomegalovirus Infection After Haploidentical Stem Cell Transplantation: The Quantitative and Qualitative Immune Recovery for Cytomegalovirus. <i>Journal of Infectious Diseases</i> , 2017, 216, 945-956.	4.0	82
328	Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e487-e496.	4.6	38
329	Effects of pre- and post-transplantation minimal residual disease on outcomes in pediatric patients with acute myeloid leukemia receiving human leukocyte antigen-matched or mismatched related donor allografts. <i>American Journal of Hematology</i> , 2017, 92, E659-E661.	4.1	19
330	Haploidentical transplantation compared with matched sibling and unrelated donor transplantation for adults with standard-risk acute lymphoblastic leukaemia in first complete remission. <i>British Journal of Haematology</i> , 2017, 179, 120-130.	2.5	70
331	Haploidentical hematopoietic stem cell transplantation for pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia in the imatinib era. <i>Leukemia Research</i> , 2017, 59, 136-141.	0.8	8
332	Concordant optimal molecular and cytogenetic responses at both 3 and 6 months predict a higher probability of MR4.5 achievement in patients with chronic myeloid leukemia treated with imatinib. <i>Leukemia and Lymphoma</i> , 2017, 58, 1384-1393.	1.3	3
333	The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission. <i>Leukemia and Lymphoma</i> , 2017, 58, 1135-1143.	1.3	27
334	The long-term outcome of reduced-intensity allogeneic stem cell transplantation from a matched related or unrelated donor, or haploidentical family donor in patients with leukemia: a retrospective analysis of data from the China RIC Cooperative Group. <i>Annals of Hematology</i> , 2017, 96, 279-288.	1.8	8
335	Higher dose of CD34+ peripheral blood stem cells is associated with better survival after haploidentical stem cell transplantation in pediatric patients. <i>Clinical Transplantation</i> , 2017, 31, e12880.	1.6	4
336	Prognostic value of lactate dehydrogenase in Chinese patients with newly diagnosed transplant eligible multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 1740-1742.	1.3	4
337	Efficacy and safety of micafungin for the treatment of patients with proven or probable invasive aspergillosis. <i>Medicine (United States)</i> , 2017, 96, e9443.	1.0	3
338	Risk factors for herpes simplex virus-1/2 viremia and clinical outcomes following unmanipulated haploidentical haematopoietic stem cell transplantation. <i>Journal of Clinical Virology</i> , 2017, 95, 20-25.	3.1	10
339	Donor-Specific Anti-Human Leukocyte Antigen Antibodies Predict Prolonged Isolated Thrombocytopenia and Inferior Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation. <i>Journal of Immunology Research</i> , 2017, 2017, 1-8.	2.2	21
340	Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL. <i>Journal of Translational Medicine</i> , 2017, 15, 184.	4.4	11
341	Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. <i>Journal of Hematology and Oncology</i> , 2017, 10, 134.	17.0	132
342	Haploidentical Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2143-2150.	2.0	19

#	ARTICLE	IF	CITATIONS
343	Risk Factors for Graft-Versus-Host Disease After Transplantation of Hematopoietic Stem Cells from Unrelated Donors in the China Marrow Donor Program. <i>Annals of Transplantation</i> , 2017, 22, 384-401.	0.9	15
344	Cysteine and glycine-rich protein 2 (<i>CSRP2</i>) transcript levels correlate with leukemia relapse and leukemia-free survival in adults with B-cell acute lymphoblastic leukemia and normal cytogenetics. <i>Oncotarget</i> , 2017, 8, 35984-36000.	1.8	23
345	CD20 expression sub-stratifies standard-risk patients with B cell precursor acute lymphoblastic leukemia. <i>Oncotarget</i> , 2017, 8, 105397-105406.	1.8	10
346	Efficacy and Safety of Bortezomib in Multiple Myeloma Patients with Hepatitis B. <i>Chinese Medical Journal</i> , 2016, 129, 274-278.	2.3	2
347	miR-153-3p, a new bio-target, is involved in the pathogenesis of acute graft-versus-host disease via inhibition of indoleamine-2,3-dioxygenase. <i>Oncotarget</i> , 2016, 7, 48321-48334.	1.8	26
348	Impact of pre-transplant pulmonary infection developed in horizontal laminar flow unit on the outcome of subsequent allogeneic hematopoietic stem cell transplantation. <i>Journal of Thoracic Disease</i> , 2016, 8, 2219-2225.	1.4	2
349	Antifungal prophylaxis of patients undergoing allogeneic hematopoietic stem cell transplantation in China: a multicenter prospective observational study. <i>Journal of Hematology and Oncology</i> , 2016, 9, 97.	17.0	20
350	Rapid Recovery of CD3+CD8+ T Cells on Day 90 Predicts Superior Survival after Unmanipulated Haploidentical Blood and Marrow Transplantation. <i>PLoS ONE</i> , 2016, 11, e0156777.	2.5	17
351	Early lymphocyte recovery predicts superior outcomes after unmanipulated haploidentical blood and marrow transplant for acute myeloid leukemia. <i>Clinical Transplantation</i> , 2016, 30, 954-958.	1.6	4
352	Transplantation from haploidentical donor is not inferior to that from identical sibling donor for patients with chronic myeloid leukemia in blast crisis or chronic phase from blast crisis. <i>Clinical Transplantation</i> , 2016, 30, 994-1001.	1.6	11
353	Haploidentical hematopoietic stem cell transplantation for paediatric high-risk T-cell acute lymphoblastic leukaemia. <i>Pediatric Transplantation</i> , 2016, 20, 572-580.	1.0	8
354	Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-versus-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes. <i>European Journal of Haematology</i> , 2016, 96, 297-308.	2.2	37
355	Adipose-Derived Mesenchymal Stem Cells (ADSCs) with the Potential to Ameliorate Platelet Recovery, Enhance Megakaryopoiesis, and Inhibit Apoptosis of Bone Marrow Cells in a Mouse Model of Radiation-Induced Thrombocytopenia. <i>Cell Transplantation</i> , 2016, 25, 261-273.	2.5	16
356	High incidence of engraftment syndrome after haploidentical allogeneic stem cell transplantation. <i>European Journal of Haematology</i> , 2016, 96, 517-526.	2.2	8
357	Atorvastatin enhances endothelial cell function in posttransplant poor graft function. <i>Blood</i> , 2016, 128, 2988-2999.	1.4	73
358	Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t(8;21). <i>Leukemia Research</i> , 2016, 44, 40-44.	0.8	29
359	Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1080-1086.	2.0	16
360	High-dose corticosteroid associated with catheter-related thrombosis after allogeneic hematopoietic stem cell transplantation. <i>Thrombosis Research</i> , 2016, 144, 6-11.	1.7	5

#	ARTICLE	IF	CITATIONS
361	Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study. <i>Clinical Cancer Research</i> , 2016, 22, 3467-3476.	7.0	142
362	Abnormalities of the bone marrow immune microenvironment in patients with immune thrombocytopenia. <i>Annals of Hematology</i> , 2016, 95, 959-965.	1.8	18
363	Controlled, Randomized, Open-Label Trial of Risk-Stratified Corticosteroid Prevention of Acute Graft-Versus-Host Disease After Haploidentical Transplantation. <i>Journal of Clinical Oncology</i> , 2016, 34, 1855-1863.	1.6	100
364	Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation in First Complete Remission Can Abrogate the Poor Outcomes of Children with Acute Myeloid Leukemia Resistant to the First Course of Induction Chemotherapy. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2235-2242.	2.0	11
365	Factors affecting the CD34+ cell yields from the second donations of healthy donors: The steady-state lymphocyte count is a good predictive factor. <i>Transfusion and Apheresis Science</i> , 2016, 55, 311-317.	1.0	2
366	Platelet-Derived Growth Factor-BB Protects Mesenchymal Stem Cells (MSCs) Derived From Immune Thrombocytopenia Patients Against Apoptosis and Senescence and Maintains MSC-Mediated Immunosuppression. <i>Stem Cells Translational Medicine</i> , 2016, 5, 1631-1643.	3.3	57
367	Clinical characteristics and risk factors of Intracranial hemorrhage in patients following allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2016, 95, 1637-1643.	1.8	27
368	Long-term survival of acute promyelocytic leukaemia patients treated with arsenic and retinoic acid. <i>British Journal of Haematology</i> , 2016, 174, 820-822.	2.5	22
369	Molecular Detection of BCR-ABL in Chronic Myeloid Leukemia. <i>Methods in Molecular Biology</i> , 2016, 1465, 1-15.	0.9	7
370	Improved clinical outcomes of rhG-CSF-mobilized blood and marrow haploidentical transplantation compared to propensity score-matched rhG-CSF-primed peripheral blood stem cell haploidentical transplantation: a multicenter study. <i>Science China Life Sciences</i> , 2016, 59, 1139-1148.	4.9	13
371	Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: A randomized study. <i>Oncolmmunology</i> , 2016, 5, e1250992.	4.6	21
372	Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant. <i>Journal of Hematology and Oncology</i> , 2016, 9, 87.	17.0	57
373	Poor CMV-specific CD8+ T central memory subset recovery at early stage post-HSCT associates with refractory and recurrent CMV reactivation. <i>Journal of Infection</i> , 2016, 73, 261-270.	3.3	19
374	Varying responses of PML-RARA with different genetic mutations to arsenic trioxide. <i>Blood</i> , 2016, 127, 243-250.	1.4	26
375	Comparison of outcomes after umbilical cord blood and unmanipulated haploidentical hematopoietic stem cell transplantation in children with high-risk acute lymphoblastic leukemia. <i>International Journal of Cancer</i> , 2016, 139, 2106-2115.	5.1	47
376	Haploidentical transplantation for acquired severe aplastic anaemia in a multicentre prospective study. <i>British Journal of Haematology</i> , 2016, 175, 265-274.	2.5	109
377	Unmanipulated haploidentical versus matched unrelated donor allogeneic stem cell transplantation in adult patients with acute myelogenous leukemia in first remission: a retrospective pair-matched comparative study of the Beijing approach with the EBMT database. <i>Haematologica</i> , 2016, 101, e352-e354.	3.5	49
378	Lower incidence of acute GVHD is associated with the rapid recovery of CD4+CD25+CD45RA+ regulatory T cells in patients who received haploidentical allografts from NIMA-mismatched donors: A retrospective (development) and prospective (validation) cohort-based study. <i>Oncolmmunology</i> , 2016, 5, e1242546.	4.6	11

#	ARTICLE	IF	CITATIONS
379	Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation. Chinese Journal of Cancer, 2016, 35, 46.	4.9	11
380	Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2016, 95, 1233-1240.	1.8	16
381	Increased Type 1 Immune Response in the Bone Marrow Immune Microenvironment of Patients with Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1376-1382.	2.0	33
382	Allogeneic hematopoietic cell transplantation for adult patients with treatment-related acute myeloid leukemia during first remission: Comparable to de novo acute myeloid leukemia. Leukemia Research, 2016, 47, 8-15.	0.8	7
383	Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia. BMC Cancer, 2016, 16, 269.	2.6	31
384	How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?. Journal of Hematology and Oncology, 2016, 9, 35.	17.0	78
385	Characterization of thrombopoietin kinetics within 60 days after allogeneic hematopoietic stem cell transplantation and its correlation with megakaryocyte ploidy distribution. Clinical Transplantation, 2016, 30, 170-178.	1.6	11
386	Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States. Biology of Blood and Marrow Transplantation, 2016, 22, 23-26.	2.0	70
387	Increased prostacyclin levels inhibit the aggregation and activation of platelets via the PI3K/AKT pathway in prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation. Thrombosis Research, 2016, 139, 1-9.	1.7	8
388	Reprint of: Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States. Biology of Blood and Marrow Transplantation, 2016, 22, S15-S18.	2.0	47
389	Combination of White Blood Cell Count at Presentation With Molecular Response at 3 Months Better Predicts Deep Molecular Responses to Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients. Medicine (United States), 2016, 95, e2486.	1.0	14
390	Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy. Medicine (United States), 2016, 95, e2560.	1.0	9
391	Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation. Oncoimmunology, 2016, 5, e1139274.	4.6	24
392	Haploidentical stem cell transplantation: anti-thymocyte globulin-based experience. Seminars in Hematology, 2016, 53, 82-89.	3.4	48
393	Combined model of the EBMT score modified model and the HCT-CI improves the stratification of high-risk patients undergoing unmanipulated haploidentical blood and marrow transplantation. Leukemia and Lymphoma, 2016, 57, 2133-2139.	1.3	8
394	Risk factors for cytomegalovirus DNAemia following haploidentical stem cell transplantation and its association with host hepatitis B virus serostatus. Journal of Clinical Virology, 2016, 75, 10-15.	3.1	21
395	<i>Helicobacter pylori</i> infection influences the severity of thrombocytopenia and its treatment response in chronic hepatitis B patients with compensatory cirrhosis: A multicenter, observational study. Platelets, 2016, 27, 223-229.	2.3	7
396	Reelin promotes the adhesion and drug resistance of multiple myeloma cells via integrin α 21 signaling and STAT3. Oncotarget, 2016, 7, 9844-9858.	1.8	39

#	ARTICLE	IF	CITATIONS
397	Increased reactive oxygen species and exhaustion of quiescent CD34-positive bone marrow cells may contribute to poor graft function after allotransplants. <i>Oncotarget</i> , 2016, 7, 30892-30906.	1.8	48
398	Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. <i>Blood</i> , 2015, 125, 2771-2778.	1.4	102
399	Fighting against hematological malignancy in China: from unique system to global impact. <i>Science China Life Sciences</i> , 2015, 58, 1183-1190.	4.9	11
400	Haploidentical stem cell transplantation in patients aged 50Âyr and older with leukemia: similar outcomes compared to younger adults. <i>Clinical Transplantation</i> , 2015, 29, 523-530.	1.6	14
401	Infusionâ€related febrile reaction after haploidentical stem cell transplantation in children is associated with higher rates of engraftment syndrome and acute graftâ€versusâ€host disease. <i>Pediatric Transplantation</i> , 2015, 19, 918-924.	1.0	11
402	Higher frequency of regulatory T cells in granulocyte colony-stimulating factor (G-CSF)-primed bone marrow grafts compared with G-CSF-primed peripheral blood grafts. <i>Journal of Translational Medicine</i> , 2015, 13, 145.	4.4	24
403	Differential impact of two doses of antithymocyte globulin conditioning on lymphocyte recovery upon haploidentical hematopoietic stem cell transplantation. <i>Journal of Translational Medicine</i> , 2015, 13, 391.	4.4	24
404	Desialylation is associated with apoptosis and phagocytosis of platelets in patients with prolonged isolated thrombocytopenia after allo-HSCT. <i>Journal of Hematology and Oncology</i> , 2015, 8, 116.	17.0	34
405	Recipient expression of ligands for donor inhibitory KIRs enhances NKâ€cell function to control leukemic relapse after haploidentical transplantation. <i>European Journal of Immunology</i> , 2015, 45, 2396-2408.	2.9	42
406	Lowâ€dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical <sc>HSCT</sc>. <i>Clinical Transplantation</i> , 2015, 29, 594-605.	1.6	16
407	Lateâ€onset Epsteinâ€Barr virusâ€related disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation is associated with impaired early recovery of <sc>T</sc> and <sc>B</sc> lymphocytes. <i>Clinical Transplantation</i> , 2015, 29, 904-910.	1.6	4
408	Febrile reaction associated with the infusion of haploidentical peripheral blood stem cells: incidence, clinical features, and risk factors. <i>Transfusion</i> , 2015, 55, 2023-2031.	1.6	16
409	The impact of donor characteristics on the immune cell composition of mixture allografts of granulocyteâ€colonyâ€stimulating factorâ€mobilized marrow harvests and peripheral blood harvests. <i>Transfusion</i> , 2015, 55, 2874-2881.	1.6	18
410	Outpatient Oral Treatment for Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 2015, 372, 884-885.	27.0	13
411	The mystery of chronic lymphocytic leukemia (CLL): Why is it absent in Asians and what does this tell us about etiology, pathogenesis and biology?. <i>Blood Reviews</i> , 2015, 29, 205-213.	5.7	59
412	Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China. <i>Tumor Biology</i> , 2015, 36, 757-767.	1.8	61
413	Reduced IL-35 levels are associated with increased platelet aggregation and activation in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2015, 94, 837-845.	1.8	6
414	Immunosuppressive treatment combined with nucleoside analog is superior to nucleoside analog only in the treatment of severe thrombocytopenia in patients with cirrhosis associated with hepatitis B in China: A multicenter, observational study. <i>Platelets</i> , 2015, 26, 672-679.	2.3	6

#	ARTICLE	IF	CITATIONS
415	Recruitment of CD8+ T cells into bone marrow might explain the suppression of megakaryocyte apoptosis through high expression of CX3CR1+ in prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2015, 94, 1689-1698.	1.8	15
416	Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase. <i>Frontiers of Medicine</i> , 2015, 9, 304-311.	3.4	7
417	The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation. <i>Annals of Hematology</i> , 2015, 94, 1699-1705.	1.8	77
418	Interferon- γ : A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1939-1947.	2.0	56
419	Combination of FVIII and low-dose rFVIIa improves haemostasis in acquired haemophilia A patients: a collaborative controlled study. <i>Thrombosis Research</i> , 2015, 135, 835-840.	1.7	3
420	Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. <i>Blood</i> , 2015, 125, 3956-3962.	1.4	387
421	Standardized fluorescence in situ hybridization testing based on an appropriate panel of probes more effectively identifies common cytogenetic abnormalities in myelodysplastic syndromes than conventional cytogenetic analysis: A multicenter prospective study of 2302 patients in China. <i>Leukemia Research</i> , 2015, 39, 530-535.	0.8	15
422	Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1110-1116.	2.0	44
423	Epidemiology, Management, and Outcome of Invasive Fungal Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation in China: A Multicenter Prospective Observational Study. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1117-1126.	2.0	81
424	Plasma microRNA-586 is a new biomarker for acute graft-versus-host disease. <i>Annals of Hematology</i> , 2015, 94, 1505-1514.	1.8	21
425	Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia. <i>Leukemia Research</i> , 2015, 39, 1319-1324.	0.8	24
426	ADAM28 overexpression regulated via the PI3K/Akt pathway is associated with relapse in de novo adult B-cell acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2015, 39, 1229-1238.	0.8	15
427	Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy. <i>Leukemia and Lymphoma</i> , 2015, 56, 3116-3123.	1.3	31
428	IL-35 inhibits acute graft-versus-host disease in a mouse model. <i>International Immunopharmacology</i> , 2015, 29, 383-392.	3.8	11
429	Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2185-2191.	2.0	46
430	Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. <i>Journal of Hematology and Oncology</i> , 2015, 8, 84.	17.0	160
431	Monocytic and promyelocytic myeloid-derived suppressor cells may contribute to CSF-induced immune tolerance in haploidentical allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2015, 90, E9-E16.	4.1	66
432	Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance. <i>Leukemia and Lymphoma</i> , 2015, 56, 2075-2081.	1.3	7

#	ARTICLE	IF	CITATIONS
433	Haploidentical hematopoietic stem cell transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia: No difference in the high- and low-risk groups. <i>International Journal of Cancer</i> , 2015, 136, 1697-1707.	5.1	42
434	Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial. <i>Annals of Hematology</i> , 2015, 94, 117-128.	1.8	26
435	Oral Arsenic and Retinoic Acid for Non-High-Risk Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 2239-2241.	27.0	94
436	Treatment outcomes in relapsed acute promyelocytic leukemia patients initially treated with all-trans retinoic acid and arsenic compound-based combined therapies. <i>Oncology Letters</i> , 2014, 7, 177-182.	1.8	15
437	Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of patients with mixed-lineage leukemia-rearranged acute leukemia: Results from a prospective, multi-center study. <i>American Journal of Hematology</i> , 2014, 89, 130-136.	4.1	15
438	Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: A comprehensive large-scale study from a single Chinese center. <i>Leukemia Research</i> , 2014, 38, 1435-1440.	0.8	63
439	Improving Cytomegalovirus-Specific T Cell Reconstitution after Haploidentical Stem Cell Transplantation. <i>Journal of Immunology Research</i> , 2014, 2014, 1-12.	2.2	22
440	Immune Reconstitution after Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 440-449.	2.0	88
441	Association between an Impaired Bone Marrow Vascular Microenvironment and Prolonged Isolated Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1190-1197.	2.0	49
442	Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia-Rearranged Acute Leukemia Who Are at High Risk of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 929-936.	2.0	28
443	Total Body Irradiation and Cyclophosphamide Plus Antithymocyte Globulin Regimen Is Well Tolerated and Promotes Stable Engraftment as a Preparative Regimen before T Cell-Replete Haploidentical Transplantation for Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1176-1182.	2.0	21
444	The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma. <i>Molecular Cancer</i> , 2014, 13, 25.	19.2	10
445	Superior Survival of Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Compared with Chemotherapy Alone Used as Post-Remission Therapy in Adults with Standard-Risk Acute Lymphoblastic Leukemia in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1314-1321.	2.0	36
446	Cytomegalovirus is a potential risk factor for late-onset hemorrhagic cystitis following allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2014, 89, 55-61.	4.1	39
447	A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value. <i>Blood</i> , 2014, 124, 1645-1654.	1.4	232
448	Haploidentical stem cell transplantation for the treatment of leukemia: current status. <i>Expert Review of Hematology</i> , 2014, 7, 635-647.	2.2	24
449	Extramedullary Relapse of Acute Leukemia after Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2023-2028.	2.0	25
450	Non-traditional CD4+CD25 ^{hi} CD69+ regulatory T cells are correlated to leukemia relapse after allogeneic hematopoietic stem cell transplantation. <i>Journal of Translational Medicine</i> , 2014, 12, 187.	4.4	12

#	ARTICLE	IF	CITATIONS
451	Multicenter phase ii study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG). <i>Journal of Hematology and Oncology</i> , 2014, 7, 59.	17.0	56
452	Mesenchymal Stem Cells versus Mesenchymal Stem Cells Combined with Cord Blood for Engraftment Failure after Autologous Hematopoietic Stem Cell Transplantation: A Pilot Prospective, Open-Label, Randomized Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 236-242.	2.0	26
453	The cell composition of infused donor lymphocyte has different impact in different types of allogeneic hematopoietic stem cell transplantation. <i>Clinical Transplantation</i> , 2014, 28, 926-934.	1.6	5
454	Resistance to Arsenic Therapy in Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 2014, 370, 1864-1866.	27.0	113
455	Who is the best donor for a related HLA haplotype-mismatched transplant?. <i>Blood</i> , 2014, 124, 843-850.	1.4	285
456	In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification. <i>Blood</i> , 2014, 124, 1880-1886.	1.4	106
457	Haplo-Identical Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome: Similar Survival in Comparison with HLA-Identical Siblings: Multi-Center, Prospective Study. <i>Blood</i> , 2014, 124, 1231-1231.	1.4	1
458	Hepatocyte Growth Factor Gene-Modified Adipose-Derived Mesenchymal Stem Cells Ameliorate Radiation Induced Liver Damage in a Rat Model. <i>PLoS ONE</i> , 2014, 9, e114670.	2.5	49
459	Interferon α : the salvage therapy for patients with unsatisfactory response to minimal residual disease-directed modified donor lymphocyte infusion. <i>Chinese Medical Journal</i> , 2014, 127, 2583-7.	2.3	14
460	Negative association of donor age with CD34 ⁺ cell dose in mixture allografts of G-CSF-primed bone marrow and G-CSF-mobilized peripheral blood harvests. <i>Chinese Medical Journal</i> , 2014, 127, 3597-601.	2.3	6
461	Immunosuppression for 6-8 weeks after modified donor lymphocyte infusion reduced acute graft-versus-host disease without influencing graft-versus-leukemia effect in haploidentical transplant. <i>Chinese Medical Journal</i> , 2014, 127, 3602-9.	2.3	16
462	Late-onset hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation in patients with advanced leukemia: differences in ATG dosage are key. <i>International Journal of Hematology</i> , 2013, 98, 89-95.	1.6	16
463	Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity. <i>Annals of Hematology</i> , 2013, 92, 1111-1119.	1.8	87
464	Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia. <i>Cancer</i> , 2013, 119, 978-985.	4.1	224
465	Advancement of human leukocyte antigen-partially matched related hematopoietic stem cell transplantation. <i>Frontiers of Medicine</i> , 2013, 7, 306-315.	3.4	0
466	Substitution of cyclophosphamide in the modified BuCy regimen with fludarabine is associated with increased incidence of severe pneumonia: a prospective, randomized study. <i>International Journal of Hematology</i> , 2013, 98, 708-715.	1.6	13
467	PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2013, 54, 1442-1449.	1.3	23
468	Epileptic seizures in patients following allogeneic hematopoietic stem cell transplantation: a retrospective analysis of incidence, risk factors, and survival rates. <i>Clinical Transplantation</i> , 2013, 27, 80-89.	1.6	18

#	ARTICLE	IF	CITATIONS
469	Association of an Impaired Bone Marrow Microenvironment with Secondary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1465-1473.	2.0	114
470	Heart failure after allogeneic hematopoietic stem cell transplantation. <i>International Journal of Cardiology</i> , 2013, 167, 2502-2506.	1.7	14
471	CD34 expression on bone marrow blasts is a novel predictor of poor prognosis independent of FLT3-ITD in acute myeloid leukemia with the NPM1-mutation. <i>Leukemia Research</i> , 2013, 37, 624-630.	0.8	21
472	Nonmalignant Late Effects in Survivors of Partially Matched Donor Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 777-783.	2.0	10
473	Donor lymphocyte infusions for relapse after allogeneic transplantation. When, if and for whom?. <i>Blood Reviews</i> , 2013, 27, 55-62.	5.7	89
474	NPM1-mutated acute myeloid leukemia of monocytic or myeloid origin exhibit distinct immunophenotypes. <i>Leukemia Research</i> , 2013, 37, 737-741.	0.8	33
475	Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 599-608.	10.7	119
476	Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABLIS or log reduction from the baseline level?. <i>Leukemia Research</i> , 2013, 37, 1035-1040.	0.8	28
477	Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2013, 88, 550-555.	4.1	45
478	Impact of Pretransplantation Risk Factors on Post Transplantation Outcome of Patients with Acute Myeloid Leukemia in Remission after Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 283-290.	2.0	36
479	Current status of stem cell therapy in China. <i>International Journal of Hematologic Oncology</i> , 2013, 2, 289-297.	1.6	0
480	High-Dose Cyclophosphamide Therapy Associated with Diffuse Alveolar Hemorrhage after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Respiration</i> , 2013, 86, 453-461.	2.6	9
481	The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) is an outcome predictor for partially matched related donor transplantation. <i>American Journal of Hematology</i> , 2013, 88, 497-502.	4.1	34
482	Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors. <i>European Journal of Haematology</i> , 2013, 91, 304-314.	2.2	55
483	Improved outcomes using G-CSF-mobilized blood and bone marrow grafts as the source of stem cells compared with G-PB after HLA-identical sibling transplantation in patients with acute leukemia. <i>Clinical Transplantation</i> , 2013, 27, 844-851.	1.6	19
484	Early lymphocyte recovery predicts superior overall survival after unmanipulated haploidentical blood and marrow transplant for myelodysplastic syndrome and acute myeloid leukemia evolving from myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 2013, 54, 2671-2677.	1.3	14
485	Donor T _H 17 cells and IL-21 may contribute to the development of chronic graft-versus-host disease after allogeneic transplantation. <i>European Journal of Immunology</i> , 2013, 43, 838-850.	2.9	23
486	Haploidentical hematopoietic stem cell transplantation without in vitro T-cell-depletion for the treatment of hematologic diseases. <i>Chimerism</i> , 2013, 4, 26-28.	0.7	7

#	ARTICLE	IF	CITATIONS
487	Oral Tetra-Arsenic Tetra-Sulfide Formula Versus Intravenous Arsenic Trioxide As First-Line Treatment of Acute Promyelocytic Leukemia: A Multicenter Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4215-4221.	1.6	149
488	MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. <i>Blood</i> , 2013, 121, 4056-4062.	1.4	277
489	Spectrum of Epstein-Barr Virus-associated Diseases in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation</i> , 2013, 96, 560-566.	1.0	34
490	Ceruloplasmin Is a Potential Biomarker for aGvHD following Allogeneic Hematopoietic Stem Cell Transplantation. <i>PLoS ONE</i> , 2013, 8, e58735.	2.5	11
491	Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label study. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2013, 51, 738-745.	0.6	36
492	Lacking Of Missing Killer-Immunoglobulin-Like Receptor Ligand In Recipients Can Predict Better Prognosis After HLA-Mismatched/Haploidentical Transplantation Without T Cells Depletion In Vitro In Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2013, 122, 2165-2165.	1.4	0
493	Comparative outcomes between cord blood transplantation and bone marrow or peripheral blood stem cell transplantation from unrelated donors in patients with hematologic malignancies: a single-institute analysis. <i>Chinese Medical Journal</i> , 2013, 126, 2499-503.	2.3	10
494	Haploidentical hematopoietic stem cell transplantation with unmanipulated granulocyte colony stimulating factor mobilized marrow and blood grafts. <i>Current Opinion in Hematology</i> , 2012, 19, 454-461.	2.5	40
495	A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of first-line therapy. <i>Future Microbiology</i> , 2012, 7, 201-209.	2.0	18
496	Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2012, 119, 3256-3262.	1.4	264
497	Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Micafungin versus Itraconazole for Prophylaxis of Invasive Fungal Infections in Patients undergoing Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1509-1516.	2.0	72
498	Haploidentical/Mismatched Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for T Cell Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 716-721.	2.0	24
499	The differences and correlations of <i>BCR-ABL</i> transcripts between peripheral blood and bone marrow assays are associated with the molecular responses in the bone marrow for chronic myelogenous leukemia. <i>American Journal of Hematology</i> , 2012, 87, 1065-1069.	4.1	15
500	Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go. <i>Journal of Hematology and Oncology</i> , 2012, 5, 10.	17.0	44
501	Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2012, 5, 29.	17.0	99
502	Haploidentical Bone Marrow Transplantation Without T-Cell Depletion. <i>Seminars in Oncology</i> , 2012, 39, 653-663.	2.2	35
503	The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. <i>Blood</i> , 2012, 119, 5584-5590.	1.4	107
504	Immune Reconstitution Following Unmanipulated HLA-Mismatched/Haploidentical Transplantation Compared with HLA-Identical Sibling Transplantation. <i>Journal of Clinical Immunology</i> , 2012, 32, 268-280.	3.8	81

#	ARTICLE	IF	CITATIONS
505	Plasma level of lipopolysaccharide-binding protein is indicative of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2012, 95, 680-688.	1.6	7
506	Characteristics and influencing factors of CD19+ B cell reconstitution in patients following haploidentical/mismatched hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2012, 96, 109-121.	1.6	11
507	The effect of HLA disparity on clinical outcome after HLA-identical blood and marrow transplantation. <i>Clinical Transplantation</i> , 2012, 26, 284-291.	1.6	39
508	Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors. <i>Clinical Transplantation</i> , 2012, 26, 868-876.	1.6	40
509	Prevention of relapse using DLI can increase survival following HLA-identical transplantation in patients with advanced-stage acute leukemia: a multi-center study. <i>Clinical Transplantation</i> , 2012, 26, 635-643.	1.6	56
510	High frequency of CD4 ⁺ CD25 ^{hi} CD69 ⁺ T cells is correlated with a low risk of acute graft-versus-host disease in allotransplants. <i>Clinical Transplantation</i> , 2012, 26, E158-67.	1.6	17
511	Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2012, 91, 183-192.	1.8	103
512	Positive Results of Serum Galactomannan Assays and Pulmonary Computed Tomography Predict the Higher Response Rate of Empirical Antifungal Therapy in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 759-764.	2.0	20
513	Immunomodulatory strategies for relapse after haploidentical hematopoietic stem cell transplantation in hematologic malignancy patients. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 351-358.	1.7	9
514	Unmanipulated HLA-Mismatched/Haploidentical Blood and Marrow Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 197-204.	2.0	58
515	Individualized Intervention Guided by BCR-ABL Transcript Levels after HLA-Identical Sibling Donor Transplantation Improves HSCT Outcomes for Patients with Chronic Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 649-656.	2.0	11
516	Superior Graft-versus-Leukemia Effect Associated with Transplantation of Haploidentical Compared with HLA-Identical Sibling Donor Grafts for High-Risk Acute Leukemia: An Historic Comparison. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 821-830.	2.0	149
517	Prolonged Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation and Its Association with a Reduction in Ploidy and an Immaturization of Megakaryocytes. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 274-280.	2.0	46
518	Conflicting Impact of Alloreactive NK Cells on Transplantation Outcomes after Haploidentical Transplantation: Do the Reconstitution Kinetics of Natural Killer Cells Create These Differences?. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1436-1442.	2.0	29
519	Characterization of CD3 ⁺ CD4 ⁺ CD8 ⁻ (double negative) T cells reconstitution in patients following hematopoietic stem-cell transplantation. <i>Transplant Immunology</i> , 2011, 25, 180-186.	1.2	18
520	Safety of Recombinant Human Thrombopoietin in Adults after Related Donor Haploidentical Haematopoietic Stem Cell Transplantation. <i>Clinical Drug Investigation</i> , 2011, 31, 135-141.	2.2	8
521	Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. <i>Blood</i> , 2011, 117, 3032-3040.	1.4	80
522	Use of G-CSF-stimulated marrow in allogeneic hematopoietic stem cell transplantation settings: a comprehensive review. <i>Clinical Transplantation</i> , 2011, 25, 13-23.	1.6	36

#	ARTICLE	IF	CITATIONS
523	Potential immunosuppressive function of plasma indoleamine 2,3-dioxygenase in patients with aGVHD after allo-HSCT. <i>Clinical Transplantation</i> , 2011, 25, E304-11.	1.6	3
524	Coinfusion of Mesenchymal Stromal Cells Facilitates Platelet Recovery Without Increasing Leukemia Recurrence in Haploidentical Hematopoietic Stem Cell Transplantation: A Randomized, Controlled Clinical Study. <i>Stem Cells and Development</i> , 2011, 20, 1679-1685.	2.1	64
525	Seven-year response to imatinib as initial treatment versus re-treatment in Chinese patients with chronic myelogenous leukemia in the chronic phase. <i>Annals of Hematology</i> , 2011, 90, 41-46.	1.8	10
526	Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2011, 90, 47-52.	1.8	49
527	The impact of graft composition on clinical outcomes in pediatric patients undergoing unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation. <i>Pediatric Blood and Cancer</i> , 2011, 57, 135-141.	1.5	19
528	Clinical impact of absolute lymphocyte count on day 30 after unmanipulated haploidentical blood and marrow transplantation for pediatric patients with hematological malignancies. <i>American Journal of Hematology</i> , 2011, 86, 227-230.	4.1	18
529	IL-17-producing T cells contribute to acute graft-versus-host disease in patients undergoing unmanipulated blood and marrow transplantation. <i>European Journal of Immunology</i> , 2011, 41, 514-526.	2.9	54
530	Aberrant expression of CKLF-like MARVEL transmembrane member 5 (CMTM5) by promoter methylation in myeloid leukemia. <i>Leukemia Research</i> , 2011, 35, 771-776.	0.8	23
531	Hematopoietic stem cell transplantation in China: current status and prospects. <i>American Journal of Blood Research</i> , 2011, 1, 90-7.	0.6	8
532	Administration of imatinib in the first 90 days after allogeneic hematopoietic cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Chinese Medical Journal</i> , 2011, 124, 246-52.	2.3	13
533	Higher proportions of peripheral CD19+CD5+ B cells predict the effect of corticosteroid in patients with late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. <i>Chinese Medical Journal</i> , 2011, 124, 1517-23.	2.3	5
534	Cytogenetic characteristics of B cell chronic lymphocytic leukemia in 275 Chinese patients by fluorescence in situ hybridization: a multicenter study. <i>Chinese Medical Journal</i> , 2011, 124, 2417-22.	2.3	9
535	Current status and development of hematopoietic stem cell transplantation in China: a report from Chinese Hematopoietic Stem Cell Transplantation Register Group. <i>Chinese Medical Journal</i> , 2011, 124, 2548-55.	2.3	4
536	A proteomic approach for plasma biomarker discovery with 8-plex iTRAQ labeling and SCX-LC-MS/MS. <i>Molecular and Cellular Biochemistry</i> , 2010, 343, 91-99.	3.1	58
537	HLA-Haploidentical Stem Cell Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, S57-S63.	2.0	37
538	Protective Immunity Transferred by Infusion of Cytomegalovirus-Specific CD8+ T Cells within Donor Grafts: Its Associations with Cytomegalovirus Reactivation Following Unmanipulated Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 994-1004.	2.0	42
539	Diarrhea during the Conditioning Regimen Is Correlated with the Occurrence of Severe Acute Graft-versus-Host Disease through Systemic Release of Inflammatory Cytokines. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1567-1575.	2.0	28
540	Safety of Recombinant Human Thrombopoietin in Adults after Related Donor Haploidentical Haematopoietic Stem Cell Transplantation. <i>Clinical Drug Investigation</i> , 2010, , 1.	2.2	1

#	ARTICLE	IF	CITATIONS
541	A novel triple-regulated oncolytic adenovirus carrying PDCD5 gene exerts potent antitumor efficacy on common human leukemic cell lines. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2009, 14, 1086-1094.	4.9	24
542	Expression of CD62L on Donor CD4+ T Cells in Allografts: Correlation with Graft-Versus-Host Disease after Unmanipulated Allogeneic Blood and Marrow Transplantation. <i>Journal of Clinical Immunology</i> , 2009, 29, 696-704.	3.8	20
543	Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up. <i>Annals of Hematology</i> , 2009, 88, 37-41.	1.8	11
544	Nucleophosmin mutations in Chinese adults with acute myelogenous leukemia. <i>Annals of Hematology</i> , 2009, 88, 159-166.	1.8	51
545	High CD4/CD8 ratio in allografts predicts adverse outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation for chronic myeloid leukemia. <i>Annals of Hematology</i> , 2009, 88, 1015-1024.	1.8	19
546	The impact of CD34 ⁺ cell dose on platelet engraftment in pediatric patients following unmanipulated haploidentical blood and marrow transplantation. <i>Pediatric Blood and Cancer</i> , 2009, 53, 1100-1106.	1.5	21
547	Treating donor mice with rhIL-11 and rhG-CSF promotes transplant-tolerance and preserves the effects of GVL after allogeneic bone marrow transplantation. <i>Leukemia Research</i> , 2009, 33, 123-128.	0.8	3
548	Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease. <i>Leukemia Research</i> , 2009, 33, 384-390.	0.8	73
549	Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for Treatment of Hematologic Malignancies in Children. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 91-94.	2.0	28
550	Treatment of Acute Leukemia with Unmanipulated HLA-Mismatched/Haploidentical Blood and Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 257-265.	2.0	278
551	First-Line Therapy for Chronic Graft-versus-Host Disease that Includes Low-Dose Methotrexate Is Associated with a High Response Rate. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 505-511.	2.0	28
552	Platelet Engraftment in Patients with Hematologic Malignancies following Unmanipulated Haploidentical Blood and Marrow Transplantation: Effects of CD34 ⁺ Cell Dose and Disease Status. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 632-638.	2.0	63
553	Expression profiles of adhesion molecules on naïve T cells in bone marrow grafts of healthy donors treated with granulocyte colony-stimulating factor. <i>Transplant Immunology</i> , 2009, 21, 228-233.	1.2	24
554	Influence of Lymphocyte Recovery on Outcome of Haploidentical Transplantation for Hematologic Malignancies. <i>Medicine (United States)</i> , 2009, 88, 322-330.	1.0	23
555	Modified Donor Lymphocyte Infusion after HLA-Mismatched/Haploidentical T Cell-replete Hematopoietic Stem Cell Transplantation for Prophylaxis of Relapse of Leukemia in Patients with Advanced Leukemia. <i>Journal of Clinical Immunology</i> , 2008, 28, 276-283.	3.8	66
556	Modified Donor Lymphocyte Infusion (DLI) for the Prophylaxis of Leukemia Relapse after Hematopoietic Stem Cell Transplantation in Patients with Advanced Leukemia—Feasibility and Safety Study. <i>Journal of Clinical Immunology</i> , 2008, 28, 390-397.	3.8	72
557	Adenovirus-mediated PDCD5 gene transfer sensitizes K562 cells to apoptosis induced by idarubicin in vitro and in vivo. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2008, 13, 641-648.	4.9	34
558	Current status of haploidentical stem cell transplantation for leukemia. <i>Journal of Hematology and Oncology</i> , 2008, 1, 27.	17.0	47

#	ARTICLE	IF	CITATIONS
559	Effects of the NK Cell Recovery on Outcomes of Unmanipulated Haploidentical Blood and Marrow Transplantation for Patients with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 323-334.	2.0	72
560	Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 469-477.	2.0	85
561	Immune-related late-onset hemorrhagic cystitis post allogeneic hematopoietic stem cell transplantation. <i>Chinese Medical Journal</i> , 2008, 121, 1766-1769.	2.3	5
562	Advance in hematopoietic stem cells transplantation for leukemia. <i>Chinese Medical Journal</i> , 2008, 121, 1763-1765.	2.3	1
563	Immune-related late-onset hemorrhagic cystitis post allogeneic hematopoietic stem cell transplantation. <i>Chinese Medical Journal</i> , 2008, 121, 1766-9.	2.3	5
564	Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. <i>Haematologica</i> , 2007, 92, 414-417.	3.5	147
565	Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. <i>Transplant Immunology</i> , 2007, 17, 193-197.	1.2	67
566	Reconstitution of Natural Killer Cell Receptor Repertoires after Unmanipulated HLA-Mismatched/Haploidentical Blood and Marrow Transplantation: Analyses of CD94:NKG2A and Killer Immunoglobulin-Like Receptor Expression and Their Associations with Clinical Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 734-744.	2.0	31
567	Modified conditioning regimen usulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma. <i>Chinese Medical Journal</i> , 2007, 120, 463-468.	2.3	8
568	Hemorrhagic cystitis following hematopoietic stem cell transplantation: incidence, risk factors and association with CMV reactivation and graft-versus-host disease. <i>Chinese Medical Journal</i> , 2007, 120, 1666-1671.	2.3	34
569	Prognosis after unmanipulated HLA-haploidentical blood and marrow transplantation is correlated to the numbers of KIR ligands in recipients. <i>European Journal of Haematology</i> , 2007, 78, 338-346.	2.2	38
570	Hemorrhagic cystitis following hematopoietic stem cell transplantation: incidence, risk factors and association with CMV reactivation and graft-versus-host disease. <i>Chinese Medical Journal</i> , 2007, 120, 1666-71.	2.3	10
571	Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. <i>Blood</i> , 2006, 107, 3065-3073.	1.4	482
572	Characteristics and prognostic factors of acute myeloid leukemia with t (8; 21) (q22; q22). <i>Zhongguo Shi Yan Xue Ye Xue Za Zhi / Zhongguo Bing Li Sheng Li Xue Hui = Journal of Experimental Hematology / Chinese Association of Pathophysiology</i> , 2005, 13, 733-40.	0.2	10
573	Effect of Recombinant Human Granulocyte Colony-Stimulating Factor on T-Lymphocyte Function and the Mechanism of This Effect. <i>International Journal of Hematology</i> , 2004, 79, 178-184.	1.6	36
574	Combined transplantation of G-CSF primed allogeneic bone marrow cells and peripheral blood stem cells in treatment of severe aplastic anemia. <i>Chinese Medical Journal</i> , 2004, 117, 604-7.	2.3	6
575	A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease. <i>Chinese Medical Journal</i> , 2004, 117, 1778-85.	2.3	19
576	An improved anti-leukemic effect achieved with donor progenitor cell infusion for relapse patients after allogeneic bone marrow transplantation. <i>Chinese Medical Journal</i> , 2003, 116, 736-41.	2.3	14

#	ARTICLE	IF	CITATIONS
577	Comparisons of Long-Term Survival and Safety of Haploidentical Hematopoietic Stem Cell Transplantation After CAR-T Cell Therapy or Chemotherapy in Pediatric Patients With First Relapse of B-Cell Acute Lymphoblastic Leukemia Based on MRD-Guided Treatment. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	3
578	Immune Reconstitution of Patients Who Recovered From Steroid-Refractory Acute Graft-Versus-Host Disease After Basiliximab Treatment. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
579	Low IL7R Expression at Diagnosis Predicted Relapse in Adult Acute Myeloid Leukemia Patients With t(8;21). <i>Frontiers in Immunology</i> , 0, 13, .	4.8	0